AUTISM ASSOCIATED GENETIC MARKERS
The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.
1 .- 27 . (canceled)
28 . A method for determining the risk of an autism spectral disorder (ASD) in a patient, the method comprising:
(a) hybridizing a DNA sample from the patient to a nucleic acid microarray comprising nucleic acid oligonucleotides specific to a plurality of single nucleotide polymorphisms (SNP) alleles and a plurality of copy number variations (CNVs) to obtain hybridization data, wherein the plurality of SNPs are present at chromosome locations chr2:73156164, chr7:150185525, chr15:39920587, chr7:40465321, chr7:91562391, chr7:92663124, chr14:23104999, chr14:94749445 and chr14:101819626, and the plurality of CNVs are located at chr2:51125559-51189547, chr6:62501698-62520254, chr6:147630445-147706364, chr7:6805237-6830596 and chr9:28180069-28337679,
(b) applying a statistical analysis to the hybridization data to determine the presence or absence of the plurality of the SNP alleles and the plurality of CNVs, wherein the statistical analysis comprises comparing the patient's hybridization data to hybridization data obtained from a negative control or positive control sample, and
(c) determining whether the patient is at risk for the ASD based on the statistical analysis.
29 . The method of claim 28 , wherein the DNA sample is amplified prior to hybridization to the microarray.
30 . The method of claim 28 , wherein the DNA sample is collected from the patient with a swab, scalpel, syringe or a scraper.
31 . The method of claim 30 , wherein the DNA sample is collected from the patient with a swab.